Johnson & Johnson is trading 4.3% down at $252.52 after its October 13 third-quarter report disappointed investors, with Middle East conflict weighing on medical-device sales.
- Sales were $25.4 billion and adjusted EPS was $2.59; adjusted EPS was slightly below one consensus estimate, despite raised full-year guidance.
- GAAP profit declined sharply, reflecting special charges for the proposed talc resolution and recent deals; Innovative Medicine performed strongly.
- Broad indices were mixed, not a clear same-direction market driver.